Market Overview

Benzinga's Top Downgrades

Benzinga's Top Downgrades
Related MNKD
14 Healthcare Stocks Fundstrat Is Buying
Support Moving Up In Mannkind Corporation
Related NVO
Novo Nordisk Says Second Phase 3A Trial With Semaglutide in People With Type 2 Diabetes Achieved Objective
Benzinga's Top Initiations

Analysts at Bank of America downgraded MannKind (NASDAQ: MNKD) from “neutral” to “underperform.” The target price for MannKind has been lowered from $8 to $5. MannKind's shares closed at $6.30 yesterday.

Swedbank downgraded Novo Nordisk A/S (NYSE: NVO) from “strong buy” to “buy.” Novo Nordisk's shares closed at $162.53 yesterday.

SunTrust Robinson Humphrey downgraded Bank of the Ozarks (NASDAQ: OZRK) from “buy” to “neutral.” The target price for Bank of the Ozarks has been raised from $46 to $49. Bank of the Ozarks' shares closed at $46.01 yesterday.

Analysts at Credit Suisse downgraded M&T Bank (NYSE: MTB) from “outperform” to “neutral.” M&T Bank's shares closed at $115.91 yesterday.

Latest Ratings for MNKD

Sep 2015Piper JaffrayDowngradesNeutralUnderweight
May 2015JP MorganDowngradesNeutralUnderweight
Mar 2015Goldman SachsDowngradesNeutralSell

View More Analyst Ratings for MNKD
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings


Related Articles (MNKD + MTB)

View Comments and Join the Discussion!

Get Benzinga's Newsletters